Clementia Pharmaceuticals, Inc.
http://clementiapharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Clementia Pharmaceuticals, Inc.
Ipsen Positive On Palovarotene Despite Troubled Past
Despite concerns over toxicity due to early growth plate closure in skeletally immature patients, Ipsen's CEO David Loew is confident that palovarotene will get through regulatory review for fibrodysplasia ossificans progressive.
Sanofi Vaccines Chief Loew To Be Ipsen CEO
Sanofi Pasteur head David Loew has been at the heart of the company's bids to develop vaccines for COVID-19 but has decided to accept a different challenge instead and take the helm at Ipsen.
New Analyses Allow Restart Of Ipsen's Palovarotene Clinical Program
Ipsen is to restart a global Phase III study of palovarotene in an ultra-rare bone disorder after additional analyses of interim data, but a partial clinical hold of the compound's use in patients aged under 14 years of age remains in place.
Ipsen Upbeat Despite Palovarotene Pain
The French drugmaker's current product portfolio is performing well but a €669m charge relating to the failure of palovarotene for the rare bone disease FOP blighted Ipsen's financials.